These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 29674277)

  • 1. Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143.
    An Q; Zhou L; Xu N
    Biomed Pharmacother; 2018 Jul; 103():415-420. PubMed ID: 29674277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long noncoding RNA NORAD acts as a ceRNA mediates gemcitabine resistance in bladder cancer by sponging miR-155-5p to regulate WEE1 expression.
    Yang Y; Zhang G; Li J; Gong R; Wang Y; Qin Y; Ping Q; Hu L
    Pathol Res Pract; 2021 Dec; 228():153676. PubMed ID: 34753061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA FOXD2-AS1 knockdown inhibits the resistance of human osteosarcoma cells to cisplatin by inhibiting miR-143 expression.
    Zhang QQ; Xu SL; Ding C; Ma CC; Yuan TS; Hua CC; Wang XH
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(2):678-686. PubMed ID: 33577022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.
    Pan J; Li X; Wu W; Xue M; Hou H; Zhai W; Chen W
    Cancer Lett; 2016 Nov; 382(1):64-76. PubMed ID: 27591936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long non-coding RNA FOXD2-AS1 promotes bladder cancer progression and recurrence through a positive feedback loop with Akt and E2F1.
    Su F; He W; Chen C; Liu M; Liu H; Xue F; Bi J; Xu D; Zhao Y; Huang J; Lin T; Jiang C
    Cell Death Dis; 2018 Feb; 9(2):233. PubMed ID: 29445134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long non-coding SBF2-AS1 acting as a competing endogenous RNA to sponge microRNA-142-3p to participate in gemcitabine resistance in pancreatic cancer via upregulating TWF1.
    Hua YQ; Zhu YD; Xie GQ; Zhang K; Sheng J; Zhu ZF; Ning ZY; Chen H; Chen Z; Meng ZQ; Liu LM
    Aging (Albany NY); 2019 Nov; 11(20):8860-8878. PubMed ID: 31619579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long noncoding RNA FOXD2-AS1 aggravates hepatocellular carcinoma tumorigenesis by regulating the miR-206/MAP3K1 axis.
    Hu W; Feng H; Xu X; Huang X; Huang X; Chen W; Hao L; Xia W
    Cancer Med; 2020 Aug; 9(15):5620-5631. PubMed ID: 32558350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
    Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
    Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing lncRNA FOXD2-AS1 inhibits proliferation, migration, invasion and drug resistance of drug-resistant glioma cells and promotes their apoptosis via microRNA-98-5p/CPEB4 axis.
    Gu N; Wang X; Di Z; Xiong J; Ma Y; Yan Y; Qian Y; Zhang Q; Yu J
    Aging (Albany NY); 2019 Nov; 11(22):10266-10283. PubMed ID: 31770107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of the Long Noncoding RNA FOXD2-AS1 Promotes Cisplatin Resistance in Esophageal Squamous Cell Carcinoma Through the miR-195/Akt/mTOR Axis.
    Liu H; Zhang J; Luo X; Zeng M; Xu L; Zhang Q; Liu H; Guo J; Xu L
    Oncol Res; 2020 Feb; 28(1):65-73. PubMed ID: 31558183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. lncRNA DLG1-AS1 promotes cervical cancer cell gemcitabine resistance by regulating miR-16-5p/HDGF.
    Zou MJ; Cheng XR; Liu RF
    J Obstet Gynaecol Res; 2022 Jul; 48(7):1836-1847. PubMed ID: 35388952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXD2-AS1 promotes malignant cell behavior in oral squamous cell carcinoma via the miR-378 g/CRABP2 axis.
    Guo S; Huang B; You Z; Luo Z; Xu D; Zhang J; Lin J
    BMC Oral Health; 2024 May; 24(1):625. PubMed ID: 38807101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA AGAP2-AS1 augments cell viability and mobility, and confers gemcitabine resistance by inhibiting miR-497 in colorectal cancer.
    Hong S; Yan Z; Song Y; Bi M; Li S
    Aging (Albany NY); 2020 Mar; 12(6):5183-5194. PubMed ID: 32202509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long noncoding FOXD2-AS1 is activated by CREB1 and promotes cell proliferation and metastasis in glioma by sponging miR-185 through targeting AKT1.
    Dong H; Cao W; Xue J
    Biochem Biophys Res Commun; 2019 Jan; 508(4):1074-1081. PubMed ID: 30553445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer.
    Xiong G; Liu C; Yang G; Feng M; Xu J; Zhao F; You L; Zhou L; Zheng L; Hu Y; Wang X; Zhang T; Zhao Y
    J Hematol Oncol; 2019 Sep; 12(1):97. PubMed ID: 31514732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. lncRNA FOXD2-AS1 Promotes the Retinoblastoma Cell Viability and Migration by Sponging miR-31.
    Liang Y; Wang H; Song R; Yin X
    Biomed Res Int; 2022; 2022():7723425. PubMed ID: 35782084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-129-5p inhibits gemcitabine resistance and promotes cell apoptosis of bladder cancer cells by targeting Wnt5a.
    Cao J; Wang Q; Wu G; Li S; Wang Q
    Int Urol Nephrol; 2018 Oct; 50(10):1811-1819. PubMed ID: 30117016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma.
    Sui C; Dong Z; Yang C; Zhang M; Dai B; Geng L; Lu J; Yang J; Xu M
    J Cell Mol Med; 2019 Sep; 23(9):6024-6033. PubMed ID: 31210410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long noncoding RNA FOXD2-AS1 promotes glioma malignancy and tumorigenesis via targeting miR-185-5p/CCND2 axis.
    Shen F; Chang H; Gao G; Zhang B; Li X; Jin B
    J Cell Biochem; 2019 Jun; 120(6):9324-9336. PubMed ID: 30520141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein.
    Chen KL; Huang SW; Yao JJ; He SW; Gong S; Tan XR; Liang YL; Li JY; Huang SY; Li YQ; Zhao Y; Qiao H; Xu S; Zang S; Ma J; Liu N
    Drug Resist Updat; 2024 Sep; 76():101111. PubMed ID: 38908233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.